On March 28, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the fiscal quarter ending February 29, 2024. The company experienced a second-quarter loss per share of $6.85, primarily due to a $5.8 billion after-tax non-cash impairment charge related to VillageMD goodwill. Despite this, adjusted earnings per share (EPS) rose by 3.4% to $1.20, attributed to a lower adjusted effective tax rate and improved U.S. Healthcare profitability. Quarterly sales increased by 6.3% year-over-year to $37.1 billion. WBA narrowed its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35, citing a challenging U.S. retail environment and other factors, while maintaining its U.S. Healthcare adjusted EBITDA guidance. The company's CEO, Tim Wentworth, expressed optimism about U.S. Healthcare's positive adjusted EBITDA and the company's execution in pharmacy services. WBA also announced a strategic portfolio review over the next three months to drive growth and deliver value.

On March 28, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the fiscal quarter ending February 29, 2024. The company experienced a second-quarter loss per share of $6.85, primarily due to a $5.8 billion after-tax non-cash impairment charge related to VillageMD goodwill. Despite this, adjusted earnings per share (EPS) rose by 3.4% to $1.20, attributed to a lower adjusted effective tax rate and improved U.S. Healthcare profitability. Quarterly sales increased by 6.3% year-over-year to $37.1 billion. WBA narrowed its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35, citing a challenging U.S. retail environment and other factors, while maintaining its U.S. Healthcare adjusted EBITDA guidance. The company's CEO, Tim Wentworth, expressed optimism about U.S. Healthcare's positive adjusted EBITDA and the company's execution in pharmacy services. WBA also announced a strategic portfolio review over the next three months to drive growth and deliver value.